Hunter Associates Investment Management LLC Has $314,000 Position in CVS Health Corp (CVS)

Hunter Associates Investment Management LLC boosted its holdings in CVS Health Corp (NYSE:CVS) by 2.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,905 shares of the pharmacy operator’s stock after acquiring an additional 100 shares during the quarter. Hunter Associates Investment Management LLC’s holdings in CVS Health were worth $314,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Gemmer Asset Management LLC boosted its position in CVS Health by 15.3% in the second quarter. Gemmer Asset Management LLC now owns 1,509 shares of the pharmacy operator’s stock valued at $121,000 after buying an additional 200 shares in the last quarter. TB Alternative Assets Ltd. acquired a new position in CVS Health in the second quarter valued at about $121,000. Captrust Financial Advisors acquired a new position in CVS Health in the second quarter valued at about $155,000. SRS Capital Advisors Inc. boosted its position in CVS Health by 48.2% in the first quarter. SRS Capital Advisors Inc. now owns 2,256 shares of the pharmacy operator’s stock valued at $177,000 after buying an additional 734 shares in the last quarter. Finally, Grace & White Inc. NY acquired a new position in CVS Health in the second quarter valued at about $199,000. 82.24% of the stock is currently owned by institutional investors and hedge funds.

CVS Health Corp (CVS) opened at $71.69 on Tuesday. CVS Health Corp has a 12-month low of $66.45 and a 12-month high of $84.72. The stock has a market cap of $76,095.96, a P/E ratio of 13.16, a PEG ratio of 1.29 and a beta of 0.89. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.55 and a current ratio of 1.05.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.49 by $0.01. The business had revenue of $46.18 billion during the quarter, compared to the consensus estimate of $46.17 billion. CVS Health had a net margin of 2.77% and a return on equity of 16.96%. CVS Health’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.64 earnings per share. research analysts anticipate that CVS Health Corp will post 5.9 EPS for the current fiscal year.

A number of research firms have commented on CVS. Loop Capital reduced their price target on shares of CVS Health from $83.00 to $73.00 and set a “hold” rating on the stock in a research report on Tuesday, November 7th. Needham & Company LLC boosted their price target on shares of CVS Health from $79.00 to $85.00 and gave the company a “buy” rating in a research report on Monday. Jefferies Group reduced their price target on shares of CVS Health from $86.00 to $76.00 and set a “hold” rating on the stock in a research report on Tuesday, November 7th. Deutsche Bank began coverage on shares of CVS Health in a research report on Monday. They issued a “buy” rating and a $90.00 price target on the stock. Finally, Oppenheimer restated a “buy” rating and issued a $95.00 price target on shares of CVS Health in a research report on Monday, October 9th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $86.35.

In related news, insider Larry J. Merlo sold 241,150 shares of the business’s stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $83.07, for a total transaction of $20,032,330.50. Following the completion of the sale, the insider now directly owns 299,255 shares of the company’s stock, valued at $24,859,112.85. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Thomas M. Moriarty sold 90,267 shares of the business’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $79.61, for a total transaction of $7,186,155.87. Following the sale, the executive vice president now directly owns 70,102 shares of the company’s stock, valued at $5,580,820.22. The disclosure for this sale can be found here. Over the last three months, insiders have sold 714,125 shares of company stock valued at $58,119,381. 0.61% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.com-unik.info/2017/12/05/hunter-associates-investment-management-llc-has-314000-position-in-cvs-health-corp-cvs.html.

CVS Health Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

What are top analysts saying about CVS Health Corp? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CVS Health Corp and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit